Skip to main content

Table 3 The changes of markers during NACT (NACT set) and whether this can predict response to chemotherapy in all patients and in those who had no macroscopic residual disease after interval-debulking surgery (R0/1)

From: The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer

Prediction chemosensitivity

Responder

Non-responder

All

R0/1

All

R0/1

CA125

Positive → negative

2/10 (20%)

2/8 (25%)

  

Positive → positive

  

6/8 (75%)

4/6 (66.7%)

DNAme

DNAme Positive → negative

7/9 (77.8%)

7/9 (77.8%)

  

DNAme Positive or negative → positive

  

6/7 (85.7%)

6/6 (100%)

  1. CA125 concentration of < 35IU/mL was deemed negative. Definitions of DNA methylation positivity are provided in Table 1. Note that amongst the 20 patients who had chemo-sensitivity data available, they were only included in the analysis if the pre- and/or post-treatment (after cycle 2) sample were positive (i.e. in 2 and 4 patients for CA125 and DNA methylation markers, respectively, neither sample was positive and hence response or lack of response could not be assessed)
Back to article page

Genome Medicine

ISSN: 1756-994X

Contact us